We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 12. | 장 마감 후 (AMC) | $-0.44 | — | — | $0 | — | 예정 |
Consensus PT $17 · 3 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2025. 10. 01. | HC Wainwright & Co. | — | 의견 유지 | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 08. 12. | HC Wainwright & Co. | — | 의견 유지 | Buy → Buy | — | HC Wainwright & Co.: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Stored first · Google News · Yahoo Finance (English)
ACXP Technical Analysis | Trend, Signals & Chart Patterns | ACURX PHARMACEUTICALS INC (NASDAQ:ACXP) - ChartMill
ACXP Technical Analysis | Trend, Signals & Chart Patterns | ACURX PHARMACEUTICALS INC (NASDAQ:ACXP) ChartMill
Acurx Pharmaceuticals (ACXP) Nudges Higher as Stock Approaches Resistance - Chandelier Stop - thelegaladvocate.com
Acurx Pharmaceuticals (ACXP) Nudges Higher as Stock Approaches Resistance - Chandelier Stop thelegaladvocate.com
Acurx Pharmaceuticals Reports First Quarter 2026 Results, Highlights Ibezapolstat Phase 3 Trial for CDI Treatment - geneonline.com
Acurx Pharmaceuticals Reports First Quarter 2026 Results, Highlights Ibezapolstat Phase 3 Trial for CDI Treatment geneonline.com
ACXP Q1 2026 Earnings: Narrowed Loss Surprises as Acurx Advances Lead Candidate - Earnings Quality Score - thelegaladvocate.com
ACXP Q1 2026 Earnings: Narrowed Loss Surprises as Acurx Advances Lead Candidate - Earnings Quality Score thelegaladvocate.com
Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat - Weatherford Democrat
Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat Weatherford Democrat
Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat